Sudarshan Pharma Industries
Sudarshan Pharma Industries (SUDARSHAN) share price was ₹37.92 at the 28 Oct 2026 close; market capitalisation ₹947 Cr; P/E (TTM) 36.82; sector Chemicals. The share price rose 61.4% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 20.1% year on year to ₹174.42 Cr and net profit rose 41.7% year on year to ₹5.61 Cr (compared with Jun 2025). Promoters held 57.81% of Sudarshan Pharma Industries in Sep 2026, down 1.12 percentage points from Jun 2026. Its Tapetide Score is 45/100 (Average) as of 28 Oct 2026.
Key Fundamentals
MicrocapSpecialty ChemicalsChemicalsPrice-based figures as of 29 Oct 2026, 10:57 IST · EPS basis: Consolidated · TTM
Peer Comparison
Commodities › Chemicals › Dyes & Pigments › Specialty Chemicals
| ₹1,362.00 | 52.34 | 1,38,635 Cr | 12.81 | 1.48% | 22.36% | 28.48% | 15,689 Cr | 2,677 Cr | |
| ₹4,243.80 | 77.05 | 46,618 Cr | 5.96 | 0.07% | 7.25% | 10.13% | 5,334 Cr | 600 Cr | |
| ₹8,352.50 | 54.22 | 42,842 Cr | 10.78 | 0.18% | 16.70% | 18.66% | 3,734 Cr | 789 Cr | |
| ₹1,580.30 | 89.13 | 20,975 Cr | 8.54 | 0.00% | 8.94% | 12.15% | 1,257 Cr | 235 Cr | |
| ₹1,487.00 | 25.89 | 20,282 Cr | 3.47 | 0.52% | 9.38% | 10.85% | 8,624 Cr | 784 Cr | |
| ₹460.60 | 31.46 | 16,701 Cr | 2.81 | 0.23% | 7.04% | 8.53% | 9,040 Cr | 531 Cr | |
| ₹5,145.00 | 19.62 | 15,148 Cr | 2.30 | 0.55% | 10.95% | 13.54% | 7,185 Cr | 788 Cr | |
| Sudarshan Pharma Industries (this company) | ₹37.76 | 36.66 | 943 Cr | 5.76 | 0.87% | 14.95% | 30.30% | 741 Cr | 25 Cr |
| Median 8 companies | ₹1,533.65 | 44.50 | 20,628 Cr | 5.86 | 0.38% | 10.17% | 12.85% | 6,260 Cr | 692 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 100/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
4- Company is expected to give good quarter
- Company has delivered good profit growth of 54.2% CAGR over last 5 years
- Promoter holding has increased by 1.54% over last quarter.
- Company's working capital requirements have reduced from 43.9 days to 17.1 days
Weaknesses
2- Stock is trading at 5.65 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
Technical Indicators
Oscillators
Bearish
Overall
Bullish
Moving Averages
Bullish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 9.12% · Jun 2026
Quarterly Results
| Particulars | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 99.2 | 129 | 116 | 162 | 145 | 169 | 168 | 221 | 174 |
| Expenses | 97.12 | 116 | 108 | 146 | 134 | 160 | 157 | 201 | 159 |
| Operating Profit | 2.08 | 13.05 | 7.97 | 15.93 | 11.04 | 9.21 | 10.87 | 20.2 | 15.9 |
| OPM % | 2.1% | 10.15% | 6.89% | 9.86% | 7.6% | 5.45% | 6.47% | 9.14% | 9.12% |
| Other Income | 0.98 | -0.85 | 0.51 | -0.81 | 1.21 | 1.86 | 1.52 | 4.13 | 1.22 |
| Interest | 3.94 | 3.7 | 4 | 4.4 | 5.96 | 5.94 | 6.28 | 7.53 | 8.21 |
| Depreciation | 0.67 | 0.67 | 0.63 | 0.83 | 0.88 | 0.9 | 0.91 | 1.09 | 1.41 |
| PBT | -1.55 | 7.83 | 3.85 | 9.89 | 5.41 | 4.23 | 5.2 | 15.71 | 7.5 |
| Tax % | -21.94% | 24.9% | 24.94% | 25.08% | 26.8% | 8.51% | 20.19% | 27.43% | 25.33% |
| Net Profit | -1.21 | 5.88 | 2.88 | 7.41 | 3.96 | 3.87 | 4.15 | 11.4 | 5.61 |
| EPS (₹) | -0.05 | 0.24 | 0.12 | 0.31 | 0.17 | 0.17 | 0.18 | 0.45 | 0.23 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 148 | 193 | 357 | 461 | 464 | 505 | 703 | 732 |
| Expenses | 143 | 186 | 346 | 446 | 441 | 465 | 652 | 676 |
| Operating Profit | 5 | 7 | 11 | 15 | 23 | 40 | 51 | 56 |
| OPM % | 3.2% | 3.7% | 3.1% | 3.2% | 4.9% | 8% | 7% | 8% |
| Other Income | 0 | 0 | 0 | 1 | 3 | 0 | 9 | 9 |
| Interest | 3 | 3 | 3 | 5 | 9 | 16 | 26 | 28 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 2 | 4 | 4 |
| PBT | 2 | 4 | 7 | 9 | 15 | 22 | 31 | 33 |
| Tax % | 26% | 25% | 26% | 26% | 25% | 26% | 23% | — |
| Net Profit | 1 | 3 | 5 | 7 | 11 | 16 | 23 | 25 |
| EPS (₹) | 0.09 | 0.19 | 0.36 | 0.29 | 0.48 | 0.66 | 0.97 | 1.03 |
| Div. Payout % | 0% | 0% | 0% | 10% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 24 | 24 | 24 | 24 |
| Reserves | 10 | 13 | 20 | 77 | 88 | 107 | 131 |
| Borrowings | 21 | 30 | 31 | 34 | 105 | 171 | 285 |
| Other Liabilities | 18 | 47 | 77 | 97 | 67 | 100 | 202 |
| Total Liabilities | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
| Fixed Assets | 6 | 6 | 6 | 20 | 26 | 48 | 104 |
| CWIP | 0 | 0 | 1 | 0 | 2 | 23 | 3 |
| Investments | 0 | 0 | 0 | 12 | 14 | 30 | 0 |
| Other Assets | 53 | 93 | 131 | 200 | 242 | 302 | 534 |
| Total Assets | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 1 | 3 | -4 | -29 | 6 | -32 | -2 |
| Investing | -3 | -1 | -1 | -26 | -5 | -21 | -78 |
| Financing | 0 | -1 | 4 | 66 | -12 | 53 | 79 |
| Net Cash Flow | -2 | 0 | -1 | 11 | -12 | 0 | -1 |
| Free Cash Flow | -4 | 1 | -5 | -43 | 2 | -54 | -51 |
| CFO/EBITDA | 20 | 50 | -19 | -179 | 36 | -74 | 7 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 114 | 75 | 64 | 96 | 116 | 121 |
| Inventory Days | 46 | 49 | 51 | 63 | 74 | 117 | 129 |
| Days Payable | 40 | 91 | 80 | 78 | 49 | 76 | 111 |
| Cash Conversion Cycle | 72 | 72 | 46 | 50 | 122 | 156 | 139 |
| Working Capital Days | 35 | 29 | 27 | 54 | 62 | 52 | 17 |
| ROCE % | — | 15% | 19% | 15% | 14% | 16% | 15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sudarshan Pharma Industries insights
62 extracted metrics + investor summaries across FY16–FY27.
Documents
Frequently Asked Questions about Sudarshan Pharma Industries
What does Sudarshan Pharma Industries Ltd do?
Where is Sudarshan Pharma Industries Ltd (SUDARSHAN) listed?
Which sector does Sudarshan Pharma Industries Ltd belong to?
What is the market capitalisation of Sudarshan Pharma Industries Ltd?
What is the PE ratio of Sudarshan Pharma Industries Ltd?
What is the 52-week high and low of Sudarshan Pharma Industries Ltd?
Does Sudarshan Pharma Industries Ltd pay dividends?
What is the Return on Equity (ROE) of Sudarshan Pharma Industries Ltd?
Company Information
Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543828.md for Sudarshan Pharma Industries Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.